Can-Fite BioPharma Ltd. (NYSE:CANF) stock opened at $2.12 in recent trading session and has moved within a range spread between a low of $1.88 and a high of $2.18. When we look at the daily trading volume, traded Can-Fite BioPharma Ltd. shares reached 269921.0, slightly lower than its 90-day average trading volume of 407370.0. The company has a market cap of $9.34 million. CANF stock lost -7.55% on the day to settle at $1.96 with a 3.86% short float and a short ratio of 0.27.
Analysts give Can-Fite BioPharma Ltd. (CANF) a recommended stock rating of 5.00 to suggest the stock is a great Strong Buy at the moment. Short term prospects for the stock appear exciting, with the distance to its 20-day simple moving average at -43.35% and the price target is given a consensus estimate of $2.62, about -1.50 down on the current stock price at $1.96. The weekly performance stands at -14.78% lower and -44.32% over the past one month. However, its overall year-to-date performance is down by -40.61% and -89.11% over the last 12 months.
If we break down the company’s shareholders to find out who the top CANF holders are, we note that insiders hold only 3.85% of the shares. The major holders are institutions that hold 14.31% of the company’s shares, specifically spread out among 9 institutional holders.
Analysts on Wall Street have given the CANF stock a steady of – for the last 3 months, with the current consensus rating among 0 polled analysts putting it at 5.00.
In terms of the stock price, analysts have given the stock a 12-month consensus price target of $1.96, with the low at $5.00 and the high at $9.00. The median price of $7.00 suggests that analysts predict the stock will gain by 72.0% over the year from the last trading price. If the stock climbs to hit the high price target, then the company’s share price would have surged by an impressive 78.22% over the next 12 months. Even hitting the consensus low price we would still see the stock rise 60.8% from its current price level.
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) is undervalued, analysts say as the stock’s 5.00 rating makes it a Strong Buy. Meanwhile, the stock that has jumped to $5.38 by losing -0.44 in Tuesday’s market deals, received rating change over the recent past. Mizuho Initiated the Buy rating. ROTH Capital Initiated the stock to Buy and has the CRVS stock price target for the year at $6. On August 24, 2017, Credit Suisse issued an Upgrade for Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) to Neutral. The target price suggests that the company shares have a 0.0 downside potential compared to its last price at the close of trade at $5.82 (up 0.04% on day’s opening price on 02/04/20).
So, what do analysts say about a stock that has dropped -1.10% year-to-date? Data shows that 4 analysts observing Corvus Pharmaceuticals Inc.’s stock have recommended CRVS as a Buy. 4 of 4 say it is a buy, while 0 rate the stock as a overweight. The remaining 0 recommend investors Hold. The median price target for the stock is $9.00, with the range between a low of $6.00 and a high of $15.00. Shares outstanding sit at 29.24M while the public float is currently at 24.35M shares.
The average analyst ratings momentum for the stock is 5.00 and has remained 5.00 and 5.00 a month ago and 2 months ago, respectively. We focus on changes in the sentiment portrayed by analysts over a given timeframe to get a pointer regarding the stock’s future price movements. If we look at the stock’s most recent price movements, the SMA20 is at a distance of 0.01% while enlarging that period further brings the SMA50 and SMA200 to 18.84% and 33.56% respectively.
In terms of volatility relative to the latest price change, CRVS has a relative strength index (RSI) of 51.50 while the ATR figure stands at 0.51. Over the last week, the stock’s price tumbled only -10.03% although that rises to 14.23% over the month. Sentiment is however tempered due to the 55.49% in quarter-over-quarter earnings a share.